Pharmacology

Pharmacology is the study of how chemical substances interact with living systems. If substances have medicinal properties, they are considered pharmaceuticals. The field encompasses drug composition and properties, interactions, toxicology, therapy, and medical applications and antipathogenic capabilities.

Pharmacology

Pharmacology is the study of the action of drugs on a biologic system. It incorporates components of medicine and biology, and how they interact with each other.

What is Pharmacodynamics?

Drug Metabolism

Caffeine Pharmacology

What is Efficacy?

Calcitonin Pharmacology

How Nasal Spray Use and Overuse Affects the Nose

Geriatric Pharmacology: Medication Management for an Aging Population

Carboplatin Pharmacology

Pharmacokinetics

Drug Excretion / Elimination

What is Toxicology?

See more featured articles »

Importance of Pharmacology in Dentistry

Infliximab Pharmacology

Olanzapine Pharmacology

Celebrex (Celecoxib) Pharmacology

Bottom-Up Approach Overview

Pharmacology of CAR-T Cells

What is Pharmacoepidemiology?

Drug Distribution

Synthetic and Patented Cannabinoids

Halicin: The AI-Discovered Antibiotic That Fights Superbugs

What is Neuropharmacology?

How Can Biochemistry Practices be made Virtual?

Importance of Allostery in Pharmacology

Pharmacology of Cannabinoid Receptors

What is Quantitative Systems Pharmacology (QSP) Modeling?

Haloperidol Pharmacology

Pharmacology of Paracetamol

What is in Silico?

Psychopharmacology and Neuropsychopharmacology Research

What is Psychopharmacology?

Warfarin Pharmacology

What Are Adaptogens-and Do They Actually Work?

What is a Dose-Response Curve?

DNA and Technology

Morphine Pharmacology

Opioid Pharmacology

Pharmacist Career

Metabolomics in Pharmacology

Hormone Pharmacology

Valproic Acid Pharmacology

Nicotine Pharmacology

What is Drug Absorption?

Latest Pharmacology News and Research

Highly potent opioid shows potential as therapy for pain and opioid use disorder

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder.

1 Apr 2026

Study reveals how extracellular matrix stiffness regulates breast cancer metastasis

A study by researchers at the University of California San Diego could make it easier to treat breast cancer by uncovering a new way the body helps prevent its spread.

31 Mar 2026

Study reveals ALDH2 vulnerability in APC-deficient colorectal cancer

A precision cancer strategy that selectively kills tumour cells while leaving healthy tissue intact may be within reach for the majority of colorectal cancer patients, according to new research published in Genes & Disease.

30 Mar 2026

Nuclera launches GPCR-focused nanodisc panel to streamline membrane protein production

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs).

From Nuclera 30 Mar 2026

UMGCCC awarded $3 million to train the next generation of oncology researchers

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has been awarded a prestigious $3 million National Cancer Institute (NCI) Career Development Award to train the next generation of oncology researchers focused on treating patients of all backgrounds.

27 Mar 2026

The new microchip electrophoresis system MultiNA II MCE-301- High sensitivity detection, improved analysis function and operability

Shimadzu has recently released the MultiNA II MCE-301 microchip electrophoresis system. By automating the entire process of electrophoresis, which takes more than two hours by hand (creation of gels, dispensing reagents, dispensing sample, separation, dyeing, cleaning of equipment), the company significantly improves the efficiency of genetic analysis operations.

From Shimadzu Europa GmbH 26 Mar 2026

UT San Antonio study evaluates rapamycin’s potential to promote healthy aging

UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio) is launching a multi-phase clinical study to better understand how the drug rapamycin may promote healthy aging.

25 Mar 2026

IGFBP1 identified as potential biomarker for IBD monitoring in elderly patients

A recent study published in Current Molecular Pharmacology highlights the potential of insulin-like growth factor binding protein 1 (IGFBP1) as a monitoring biomarker for disease activity in elderly patients with inflammatory bowel disease (IBD).

24 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Research reveals potential new strategy for targeting deadly small cell neuroendocrine cancers

UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment.

23 Mar 2026

Study links gut microbiome imbalance to worsening kidney disease

Researchers at UC Davis School of Medicine have uncovered how an imbalanced gut microbiome escalates the production of metabolic byproducts by certain gut bacteria.

19 Mar 2026

Study identifies protein biomarker and potential treatment for schizophrenia

Current schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms like disorganized thinking or executive dysfunction.

19 Mar 2026

Implantable device boosts immune cells to fight cancer effectively

Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease.

17 Mar 2026

Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

15 Mar 2026

Marburg virus enters human cells far more efficiently than Ebola

In a new study published in Nature, University of Minnesota researchers found that the Marburg virus, one of the world's deadliest pathogens with an average 73% fatality rate, is unusually efficient at getting inside human cells.

11 Mar 2026

Viagra ingredient improves symptoms in patients with Leigh syndrome

Sildenafil – an active ingredient also marketed under the name of Viagra – improves symptoms in patients with Leigh syndrome.

11 Mar 2026

Single receptor PAR1 controls opposing responses in blood vessels

Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels - one inflammatory and one protective.

10 Mar 2026

FOXJ1 gene may drive resistance to taxane chemotherapy in advanced prostate cancer

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center.

10 Mar 2026

Tubulin prevents toxic protein clumps linked to neurodegeneration

Researchers at Baylor College of Medicine have discovered a potential new strategy to fight back against Alzheimer's and Parkinson's diseases, conditions that are linked to the toxic accumulation of Tau and alpha synuclein protein clumps in the brain.

6 Mar 2026

PET imaging reveals molecular mechanism behind ketamine's antidepressant effects

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies.

6 Mar 2026